Lipum AB (publ) has signed an agreement with Flerie Invest AB including a loan commitment of SEK 20 million. The agreement which has been signed on market terms, enters into force on 1 June 2024, has a term of 12 months and runs without collateral.

"We are in a very intense phase with the completion of the clinical phase 1 study as well as we intend to start the planning of a phase 2 study. At the same time, we run several preclinical initiatives where we need flexibility in optimizing the execution. With this loan commitment, we get a security to carry out the activities without unnecessary delay. I am very pleased with the support we receive from our major shareholder Flerie Invest ", says Ola Sandborgh, CEO of Lipum.

Contacts
Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

This information is information that Lipum is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-06 09:00 CEST.

Attachments
Lipum receives loan commitment of SEK 20 million

Lipum receives loan commitment of SEK 20 million